Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: Executive Summary of a European and Asia-Pacific Expert Consensus Paper
Diana A. Gorog(University of Hertfordshire), Gregory Y.H. Lip(University of Liverpool), José Luis Ferreiro(Institut d'Investigació Biomédica de Bellvitge), Francisco Marı́n(Universidad de Murcia), Stavros V. Konstantinidis(Johannes Gutenberg University Mainz), Laurent Fauchier(Université de Tours), Ying X. Gue(University of Liverpool), Andrea Rubboli, Hung‐Fat Tse(Queen Mary Hospital), Tatjana Potpara, Vanessa Roldán(Hospital Universitario Virgen de la Arrixaca), Kurt Huber(Sigmund Freud Privatuniversität Wien), Dirk Sibbing(LMU Klinikum), Gemma Vilahur(Hospital de Sant Pau), Tze‐Fan Chao(National Yang Ming Chiao Tung University), Jonas Oldgren, Deirdre A. Lane(University of Birmingham)
Cited by 113
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
|European Heart Journal|2022|3.6k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k